apoL11a Inhibitors
Chemical inhibitors of apolipoprotein L 11a function by interfering with various cellular signaling pathways and processes that are essential for the protein's activity. Alisertib, for instance, targets aurora kinase A, a key regulator of mitosis, disrupting proper chromosome alignment and segregation. This disruption can indirectly lead to the inhibition of apolipoprotein L 11a by impeding its proper folding or secretion in dividing cells. Similarly, Palbociclib's mechanism involves the inhibition of cyclin-dependent kinases, CDK4 and CDK6, which are pivotal for cell cycle progression. This results in a reduction of factors necessary for apolipoprotein L 11a's role in cell growth and viability.
The MAPK/ERK pathway, critical for post-translational modifications of many proteins, including apolipoprotein L 11a, can be inhibited by Trametinib, which targets MEK1 and MEK2. This inhibition can lead to a decrease in apolipoprotein L 11a's functional activity. LY294002 and Omipalisib both target signaling pathways integral for cell survival and metabolism – with LY294002 being a PI3K inhibitor and Omipalisib inhibiting both PI3K and mTOR. The inhibition of these pathways can alter the post-translational environment of apolipoprotein L 11a, thereby decreasing its functional activity. Dasatinib, by inhibiting Src family kinases, can disrupt various signaling pathways that might otherwise stabilize or facilitate apolipoprotein L 11a's function within the cell. Venetoclax, targeting the Bcl-2 protein and promoting apoptosis, can reduce the number of viable cells expressing apolipoprotein L 11a, thus indirectly reducing the protein's functional capacity. Thalidomide works by affecting the ubiquitin-proteasome system, potentially decreasing the degradation of proteins that regulate apolipoprotein L 11a activity. Ibrutinib's irreversible binding to Bruton's tyrosine kinase results in altered cellular signaling that can inhibit factors involved in apolipoprotein L 11a's stability or function. Rapamycin, through its inhibition of mTOR, can lead to a decrease in cellular processes essential for apolipoprotein L 11a's full functional expression. Lastly, Ruxolitinib's inhibition of JAK1 and JAK2 can disrupt cytokine signaling crucial for maintaining the cellular conditions favorable to apolipoprotein L 11a's activity, while Sorafenib's inhibition of RAF kinases can lead to reduced activation of proteins in the MAPK/ERK pathway, further impacting apolipoprotein L 11a.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
Alisertib inhibits aurora kinase A, which is essential for proper chromosome alignment and segregation during mitosis. Inhibition of aurora kinase A can disrupt the cell cycle and indirectly lead to the inhibition of apolipoprotein L 11a by preventing its proper assembly or secretion in dividing cells. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib inhibits cyclin-dependent kinases CDK4 and CDK6, which play a role in cell cycle progression. As apolipoprotein L 11a is involved in cell growth and viability, palbociclib's inhibition of the cell cycle can result in decreased availability of factors necessary for apolipoprotein L 11a function. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib inhibits MEK1 and MEK2, components of the MAPK/ERK pathway. Apolipoprotein L 11a is reliant on this pathway for post-translational modifications; thus, trametinib's inhibition of MEK can lead to reduced functional activity of apolipoprotein L 11a. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that disrupts the PI3K/AKT signaling pathway. As this pathway is integral to many cellular processes, including survival and metabolism, inhibition by LY294002 can decrease the functional activity of apolipoprotein L 11a by altering its post-translational environment. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. Src kinases can influence various signaling pathways that modulate cell survival and proliferation. Inhibition by dasatinib may disrupt signaling necessary for the proper function of apolipoprotein L 11a. | ||||||
GSK2126458 | 1086062-66-9 | sc-364503 sc-364503A | 2 mg 10 mg | $260.00 $1029.00 | ||
Omipalisib inhibits both PI3K and mTOR, which are part of the cellular growth and survival pathways. By inhibiting these pathways, omipalisib can reduce the activity of factors that facilitate the functional state of apolipoprotein L 11a. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
ABT-199 targets the Bcl-2 protein, an important regulator of apoptosis. By promoting apoptosis, ABT-199 can decrease cell viability and indirectly reduce the functional capacity of apolipoprotein L 11a in cells undergoing programmed cell death. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide inhibits the cereblon-DDB1-Cul4A E3 ubiquitin ligase complex. This inhibition can affect the ubiquitin-proteasome system, potentially decreasing the degradation of regulatory proteins that normally inhibit apolipoprotein L 11a function. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib irreversibly binds to Bruton's tyrosine kinase (BTK), leading to an inhibition of B-cell receptor signaling. This inhibition can alter cellular signaling cascades, potentially inhibiting processes or factors that stabilize or facilitate the function of apolipoprotein L 11a. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and inhibits mTOR, a central regulator of cell growth and metabolism. This action can lead to a decrease in cellular processes that are necessary for the full functional expression of apolipoprotein L 11a. | ||||||